The Brown University Child & Adolescent Psychopharmacology Update

Clozapine REMS removed, but neutropenia risk still requires monitoring, and some clinicians are still wary

15 October 2026Original research1 min read

Abstract

Saying that the Risk Evaluation and Mitigation Strategies (REMS) program for clozapine may prevent access to treatment, the Food and Drug Administration (FDA) last year said the REMS is no longer necessary.

Keywords

Schizophrenia research and treatment
clozapine
risk evaluation and mitigation strategy

Read around a topic while you study.

Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.

Discover Ward

neutropenia

adverse drug reactions

antipsychotic safety

treatment access

FDA regulatory policy

patient monitoring

Open access

Source

Published in The Brown University Child & Adolescent Psychopharmacology Update. The abstract is shown as published and remains the work of its authors; read the full article at the source.

doi.org/10.1002/cpu.31104

Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.

At a glance

Journal: The Brown University Child & Adolescent Psychopharmacology Update
Type: Original research
Published: 15 October 2026
Specialty: Psychiatry
Read time: 1 min
DOI: 10.1002/cpu.31104